Trials / Completed
CompletedNCT00047645
A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 330 (actual)
- Sponsor
- InterMune · Industry
- Sex
- All
- Age
- 20 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
Study GIPF-001 is phase 3 study designed to determine the safety and efficacy of IFN-g 1b administered by subcutaneous injection; compared to placebo in patients with IPF who are unresponsive to steroids. 330 patients have been enrolled and were assigned to either a IFN-g 1b group or a placebo group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Interferon-gamma 1b | 200 mcg, SQ, 3x per week |
Timeline
- Start date
- 2000-04-01
- Completion
- 2002-12-01
- First posted
- 2002-10-11
- Last updated
- 2007-11-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00047645. Inclusion in this directory is not an endorsement.